Range Nuclear Renaissance ETF vs Recursion Pharmaceuticals Inc — how do they compare? Range Nuclear Renaissance ETF trades at $61.26 (market cap $698.21M), while Recursion Pharmaceuticals Inc trades at $4.36 (market cap $2.14B). The key difference: Recursion Pharmaceuticals Inc is far larger — about 3.1× Range Nuclear Renaissance ETF's market cap, and Recursion Pharmaceuticals Inc is trading nearer its 52-week high, Range Nuclear Renaissance ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Range Nuclear Renaissance ETF for 18 Days and Recursion Pharmaceuticals Inc for 23 Days on average.
| NUKZ | RXRX | |
|---|---|---|
Market Cap | $698.21M | $2.14B |
Volume | 57,444 | 30,789,535 |
Sector | Sector/Thematic | Health |
52-Week High | $76.23 | $6.79 |
52-Week Low | $60.23 | $2.84 |
Typical Hold Time | 18 Days | 23 Days |
Enterprise Value | — | $1.66B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Recursion Pharmaceuticals (RXRX) trades at $3.95, down 7.49% today, with a mixed technical picture showing bullish moving averages but neutral oscillators. The company reported Q2 2026 earnings miss after two consecutive beats, while maintaining negative profitability metrics with a -961.97% net income margin. Recent strategic partnerships with Tempus and Roche aim to expand the AI-driven drug discovery pipeline through 2028.
RXRX presents high-risk growth potential with strong analyst support (40% buy rating) but faces substantial financial challenges including persistent losses and negative cash flow from operations. The stock's investment case hinges on successful pipeline development and partnership monetization, though current valuation appears stretched at 37.14x sales given the lack of profitability.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Range Nuclear Renaissance ETF seeks to track companies related to the nuclear energy industry. Its holdings may include businesses involved in uranium, nuclear power generation, reactors, and nuclear services.
Read more on NUKZ →Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →